Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells

Basit Öğe Kaydı
dc.authorid0000-0001-7369-0426
dc.contributor.authorYerlikaya, Azmi
dc.contributor.authorAltıkat, Sayit
dc.contributor.authorIrmak, Reyhan
dc.contributor.authorCavga, Fatma Zehra
dc.contributor.authorKocacan, Sultan Aysun
dc.contributor.authorBoyacı, İhsan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:50Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:50Z
dc.date.issued2013
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000321079300046
dc.descriptionPubMed ID: 23660746
dc.description.abstractBortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approved for the treatment of patients with relapsed and refractory multiple myeloma. A number of studies have been conducted to evaluate. the activity and safety of bortezomib either alone or in combination with several cytotoxic agents and radiation. In the current study, the efficacy of bortezomib alone or in combination with cisplatin and 5-fluorouracil was evaluated in 4T1 breast cancer cells, a highly metastatic murine cancer cell line. Using MTT assay, IC50 values of cisplatin and 5-fluorouracil were determined to be 14.2 and 8.9 mu M for cisplatin and 5-fluorouracil, respectively. The effects of different concentrations of cisplatin and 5-fluorouracil in combination with two different concentrations of bortezomib were examined in the 4T1 cells. Statistically significant differences were found when 1 or 5 mu M cisplatin was combined with 10 or 50 nM bortezomib. Similarly, 1 mu M 5-fluorouracil or 5 mu M 5-fluorouracil in combination with 10 nM bortezomib caused significant cell death as compared to treatment with single agents. However, 1 or 5 mu M 5-fluorouracil did not potentiate the effects of higher concentrations of bortezomib (50 nM). The effect of the combination of cisplatin, 5-fluorouracil and bortezomib was determined by soft agar assay. It was confirmed that a combination of cisplatin and bortezomib was more effective than each drug as a monotherapy. Therefore, the combination of cisplatin and bortezomib should be tested further in clinical settings.
dc.identifier.citationYerlikaya, A., Altıkat, S., Irmak, R., Cavga, F. Z., Kocacan, S. A. ve Boyacı, İ. (2013). Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells. Molecular Medicine Reports, 8(1), 277-281. https://dx.doi.org/10.3892/mmr.2013.1466
dc.identifier.doi10.3892/mmr.2013.1466
dc.identifier.endpage281
dc.identifier.issn1791-2997
dc.identifier.issn1791-3004
dc.identifier.issue1
dc.identifier.scopusqualityQ3
dc.identifier.startpage277
dc.identifier.urihttps://dx.doi.org/10.3892/mmr.2013.1466
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3459
dc.identifier.volume8
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpandidos Publications
dc.relation.ispartofMolecular Medicine Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBortezomib
dc.subjectCancer
dc.subjectCisplatin
dc.subject5-Fluorouracil
dc.titleEffect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Boyacı-Ihsan 2013.pdf
Boyut:
524.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu